Personalis EBITDA 2018-2024 | PSNL
Personalis ebitda from 2018 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Personalis Annual EBITDA (Millions of US $) |
2023 |
$-101 |
2022 |
$-107 |
2021 |
$-57 |
2020 |
$-36 |
2019 |
$-18 |
2018 |
$-11 |
2017 |
$-21 |
Personalis Quarterly EBITDA (Millions of US $) |
2024-09-30 |
$-12 |
2024-06-30 |
$-15 |
2024-03-31 |
$-17 |
2023-12-31 |
$-22 |
2023-09-30 |
$-29 |
2023-06-30 |
$-23 |
2023-03-31 |
$-27 |
2022-12-31 |
$-29 |
2022-09-30 |
$-25 |
2022-06-30 |
$-26 |
2022-03-31 |
$-26 |
2021-12-31 |
$-18 |
2021-09-30 |
$-16 |
2021-06-30 |
$-13 |
2021-03-31 |
$-10 |
2020-12-31 |
$-12 |
2020-09-30 |
$-8 |
2020-06-30 |
$-8 |
2020-03-31 |
$-8 |
2019-12-31 |
$-6 |
2019-09-30 |
$-5 |
2019-06-30 |
$-3 |
2019-03-31 |
$-4 |
2018-12-31 |
|
2018-09-30 |
$-1 |
2018-06-30 |
$-4 |
2017-12-31 |
|
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Medical - Generic Drugs |
$0.245B |
$0.073B |
Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.
|